Drug intelligence / Profile preview

META-2

Development stage: Preclinical
Lead developer: META Pharmaceuticals
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Subcutaneous, Intravenous

Overview

META-2 is a monoclonal antibody being developed by META Pharmaceuticals for the treatment of metabolic diseases, specifically obesity. As part of META Pharmaceuticals' focus on immunometabolism, META-2 is designed to modulate metabolic pathways through an antibody-based approach. While the specific biological target of the antibody has not been publicly disclosed by the developer, the program is positioned as a first-in-class or novel therapeutic candidate within the company's pipeline. It is currently in the early stages of development, typically characterized as preclinical or IND-enabling.

Beyond the preview

Go deeper on META-2.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on META-2.

Explore the full profile